{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.94","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Hepatocellular Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.60","upperLimit":"7.46","value":"5.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Triple Negative Breast Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Immune Checkpoint-naïve Melanoma"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Primary Refractory Melanoma"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.60","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Relapsed Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.72","upperLimit":"24.38","value":"14.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"NSCLC"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"18.40","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Renal Cell Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.37","upperLimit":"15.41","value":"8.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of the Head and Neck"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.41","upperLimit":"NA","value":"13.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Transitional Cell Carcinoma of the GU Tract"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.34","upperLimit":"25.92","value":"13.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.97","upperLimit":"15.84","value":"4.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Gastric Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.15","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"MSI high Colorectal Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"4.37","upperLimit":"NA","value":"11.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"DLBCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"description":"Overall survival is determined from the date of first dose until death due to any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG000","title":"Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"The Efficacy Evaluable Population included all participants enrolled in the study who received at least 1 dose of study drug. Number analyzed indicated participants analyzed in the respective tumor type. The median time and the 90% CI were estimated using Kaplan-Meier method.","reportingStatus":"POSTED","timeFrame":"Up to 54 months","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}